Amylyx Pharmaceuticals, Inc.

NASDAQ•AMLX

CEO: Mr. Joshua B. Cohen

セクター: Healthcare

業種: Biotechnology

上場日: 2022-01-07

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

連絡先情報

43 Thorndike Street, Cambridge, MA, 02141, United States

617-682-0917

amylyx.com

時価総額

$1.15B

PER (TTM)

-9.0

18.8

配当利回り

52週高値

$17.49

52週安値

$3.11

52週レンジ

75%

順位43Top 50.7%

3.8

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 3.8 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.28+0.00%

直近4四半期の推移

フリーCF

-$27.99M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Reduced Net Loss Net loss improved to 144.7M USD in 2025 from 301.7M USD in 2024, representing a 52% reduction in annual losses.

Strong Cash Position Cash, cash equivalents, and marketable securities totaled 317.0M USD as of December 31, 2025, sufficient to fund operations into 2028.

Operating Expenses Decreased Operating expenses fell 62% to 153.3M USD in 2025, driven by restructuring and the discontinuation of commercial operations for RELYVRIO/ALBRIOZA.

リスク要因

Zero Product Revenue Product revenue dropped to 0 USD in 2025 following the voluntary discontinuation of RELYVRIO/ALBRIOZA, creating uncertainty for future financial sustainability.

Third-Party Manufacturing Risks Reliance on third-party manufacturers for clinical and commercial supply poses risks of supply chain disruptions and increased production costs for candidates.

Clinical Development Uncertainty Clinical development is highly speculative; failure to achieve positive results in ongoing trials for avexitide or AMX0035 could severely harm prospects.

見通し

Pipeline Development Focus Prioritize clinical development of pipeline, including Phase 3 LUCIDITY trial for avexitide in PBH, with topline data expected in Q3 2026.

Strategic Growth Initiatives Actively evaluate strategic opportunities, including potential in-licensing or acquisitions, to expand pipeline and leverage existing expertise in rare disease indications.

Disciplined Capital Allocation Maintain disciplined capital allocation to support ongoing research and development, while seeking additional funding or collaborations to extend operational runway.

同業比較

売上高 (TTM)

SNDX

$172.35M

+627.8%

IMTX

$93.54M

-26.7%

SYRE

$90.49M

+0.0%

粗利益率 (最新四半期)

SNDX

102.3%

-13.9pp

IMTX

100.0%

+0.0pp

ATAI

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
WVE	$2.47B	-11.6	-85.0%	2.8%
SYRE	$2.43B	-89.5	-29.4%	0.0%
SNDX	$1.95B	-6.7	-206.6%	65.4%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月1日

EPS:-$0.35

売上高:-$52.00K

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし